39429 - NHS: Logos (Answered)

Justin Madders
To ask the Secretary of State for Health, pursuant to the Answer of 6 June 2016 to Question 38480, whether his Department is taking steps in response to use of the NHS logo by the Vote Leave Campaign.

George Freeman

Vote Leave is not authorised to use the National Health Service trademark, or an adaptation of it.

The Department has sought legal advice and has been in contact with the Vote Leave campaign about misuse of the NHS brand.

39109 - Infectious Diseases: Drugs (Answered)

Catherine West
To ask the Secretary of State for Health, which organisation has responsibility for commissioning drugs that prevent the contraction of infectious diseases.

George Freeman

Bacteria and viruses cause a wide range of infectious diseases. Clinical commissioning groups, NHS England and local authorities all have commissioning responsibilities in respect of provision of drugs that prevent infectious diseases.

38965 - Brain: Tumours (Answered)

Toby Perkins
To ask the Secretary of State for Health, if his Department will increase funding for research into brain tumours.

George Freeman

39035 - PrescQIPP (Answered)

Kevin Brennan
To ask the Secretary of State for Health, what measures his Department has in place to ensure that PrescQIPP is accountable for the safety of its guidance to clinical commissioning groups.

George Freeman

PrescQIPP is an independent social enterprise and these are matters for the company. We understand that PrescQIPP has a quality assurance process in place to ensure the quality and evidence base of its guidance resources are of the highest standard. Further information is available at:

39034 - PrescQIPP (Answered)

Kevin Brennan
To ask the Secretary of State for Health, what steps his Department is taking to ensure that PrescQIPP (a) is accountable for its guidance to clinical commissioning groups and (b) adheres to all appropriate quality standards in its work.

George Freeman

39005 - Antibiotics: Research (Answered)

David Simpson
To ask the Secretary of State for Health, how much public funding has been provided for research into new alternatives to antibiotics in each of the last five years.

George Freeman

The information requested is not available.

39248 - Fibromyalgia: Research (Answered)

David Simpson
To ask the Secretary of State for Health, what steps his Department is taking to fund fibromyalgia research.

George Freeman

The Department's National Institute for Health Research welcomes funding applications for research into any aspect of human health, including fibromyalgia. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality.

38895 - Neuroendocrine Cancer: Drugs (Answered)

Mr Nicholas Brown
To ask the Secretary of State for Health, with reference to findings presented at the 2015 European Cancer Congress on Lutathera, what assessment he has made of the reported benefits of that drug on treating patients with neuroendocrine tumours.

George Freeman

The clinical research findings on Lutathera, presented to the European Cancer Congress, have not yet been published in a peer-reviewed journal.

38894 - Cancer: Drugs (Answered)

Mr Nicholas Brown
To ask the Secretary of State for Health, for what reasons the Lutathera drug was removed from the list of drugs available under the Cancer Drugs Fund.

George Freeman

Peptide receptor radionuclide therapy (including Luththera) for the treatment of gastro-entero-pancreatic neuroendocrine tumours was removed from the Cancer Drugs Fund in November 2015 on the grounds that it represented insufficient value for retention within the Fund.

NHS England’s full decision summary is available at:

38897 - Neuroendocrine Cancer (Answered)

Mr Nicholas Brown
To ask the Secretary of State for Health, what information his Department holds on the use of peptide receptor radionuclide therapy treatments to target carcinoid tumours.

George Freeman

Information on the peptide receptor radionuclide therapy treatments funded through the Cancer Drugs Fund (CDF) is shown in the table. It is not known for what type of cancer these treatments have been provided.

Number of patients treated in 2011/121

Pages